Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05551273 · ClinicalTrials.gov registry record · Phase 2
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
A Phase 2 study of HIV Infections and Hepatitis B, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT05551273 is a Phase 2 study of HIV Infections and Hepatitis B that is active but no longer recruiting, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 29 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05551273, a Phase 2 study of HIV Infections and Hepatitis B, is active but no longer recruiting, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level \>1000 (3 log10) IU/mL at screening. The study will also evaluate if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Selgantolimod
Study Locations (20)
Other
- Hospital Nossa Senhora da Conceicao CRS - Porto Alegre
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS Site ID# 12101 - Rio de Janeiro
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS - Rio de Janeiro
- GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS - Port-au-Prince
New York
- Weill Cornell Chelsea CRS - New York
- Columbia P&S CRS - New York
- Weill Cornell Uptown CRS - New York
Ohio
- Cincinnati Children's Hosp / Univ Hosp - Cincinnati
- Case CRS Site ID# 2501 - Cleveland
- Ohio State University CRS - Columbus
North Carolina
- Chapel Hill CRS - Chapel Hill
- Greensboro CRS Site# 3203 - Greensboro
Alabama
- Alabama CRS - Birmingham
California
- UCSD Antiviral Research Center CRS - San Diego
Georgia
- The Ponce de Leon Center CRS - Atlanta
Illinois
- Northwestern University CRS - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-05-05 |
| Est. Completion | 2026-04-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05551273
The ClinicalTrials.gov registry entry for NCT05551273 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05551273 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Ohio.
Frequently Asked Questions
What is clinical trial NCT05551273 about?
NCT05551273 is a clinical study titled "Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV". The study aims to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both CHB and HIV who have been receiving suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level \>1000 (3 log10) ...
What is the current status of trial NCT05551273?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2023-05-05. Estimated completion is 2026-04-29.
What conditions does trial NCT05551273 study?
This clinical trial studies the following conditions: HIV Infections, Hepatitis B.
What interventions are being tested in trial NCT05551273?
The interventions under investigation include: Placebo (DRUG), Selgantolimod (DRUG).
Who is sponsoring clinical trial NCT05551273?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05551273 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.